Medicure Announces New Partnership Through Its Marley Drug Subsidiary to Provide Brenzavvy(R) as an Affordable Medication for Americans with Type 2 Diabetes

WINNIPEG, MB / ACCESSWIRE / December 5, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, through its pharmacy subsidiary Marley Drug, a trusted national pharmacy known for its commitment to affordable healthcare solutions, is pleased to announce a partnership with TheracosBio to distribute a newly approved diabetes drug, BRENZAVVY (bexagliflozin) tablets, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, at an affordable cash price delivered directly to patient homes in all 50 US states and territories.

"Our success with ZYPITAMAG has attracted attention from other companies to distribute their products outside of the traditional channels, and our newest addition is BRENZAVVY, which has significant potential for the $26 Billion SGLT-2 diabetes market in the United States", said Dr. Albert D. Friesen, CEO and Chairman of the Board. "This partnership with TheracosBio represents a significant step forward in our mission to enhance patient care and provide affordable medications to those in need."

Approximately 37 million Americans, which equates to roughly 11% of the population, are currently afflicted by type 2 diabetes, and leads to the highest healthcare expenditures in the United States.¹

Approved in 2023, BRENZAVVY is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, including those with chronic kidney disease that has progressed to stage 3.² It is a direct competitor of SGLT-2 inhibitors JARDIANCE, FARXIGA, INVOKANA and STEGLATRO, for which more than 25% of the potential patients cannot access due to cost and limited insurance coverage.³

"We know from our experience with ZYPITAMAG that patients and healthcare providers are exhausted by rejected and complex insurance claims and high copays, and we believe that every individual deserves access to quality healthcare," stated Dr. Friesen. "By offering BRENZAVVY at an affordable cash price, we hope to positively impact the lives of those living with diabetes and support them in their journey towards better health."

Under the partnership with TheracosBio, the manufacturer of BRENZAVVY, Marley Drug will offer the therapy at an affordable cash price, ensuring that individuals with diabetes can obtain the medication without fear of rejection from an insurance company and at an affordable price. This collaboration aligns with Medicure and Marley Drug's mission to provide innovative and accessible healthcare solutions to improve patient care and well-being. Read more at www.marleydrug.com/brenzavvy-bexagliflozin.